Trial Profile
A Phase I Study of the DA-3030 Injection to Evaluate Its Safety and Explore the Efficacy for Diabetic Neuropathic Pain
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2016
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions
- Sponsors Dong-A ST
- 30 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2013 New trial record